Exploring the Potential of ctDNA-MRD for Recurrence Surveillance and Prognostic Evaluation in High-risk Endometrial Cancer

Summary

Patients with high-risk endometrial cancer may have MRD after surgical treatment, which is a potential source of follow-up early recurrence and metastasis, and because of its limited resolution, traditional imaging (including PET/CT) or laboratory methods may not be reliable to detect. For patients with radical treatment, the uncured population can be identified by the detection of MRD, suggesting that patients may benefit from further intervention. The purpose of this study is to explore the prognostic value and recurrence monitoring value of ctDNA-MRD in patients with endometrial carcinoma.

Eligibility

Inclusion Criteria:

* (1) endometrial carcinoma with high risk of recurrence after radical surgery: stage I G3 endometrioid carcinoma, serous carcinoma, clear cell carcinoma, carcinosarcoma, dedifferentiated / undifferentiated carcinoma, II-IV stage endometrial carcinoma, operable recurrent endometrial carcinoma.

  (2) the physical status (PS) score of the eastern tumor tissue cooperation group (ECOG) was 0 or 1.

  (3) the treatment process should cooperate with the provision of clinicopathological and imaging data needed for the research process.

  (4) cooperate with the follow-up and collect the blood of the clinical curative effect evaluation node, and agree to use the test data for follow-up research and product development.

  (5) after operation, imaging examination showed no evidence of local disease or distant metastasis.

Exclusion Criteria:

* (1) histological diagnosis of endometrial stromal sarcoma.

  (2) there are contraindications of radiotherapy and chemotherapy.

  (3) any other patients who may have poor compliance with the procedures and requirements of the study have been judged by the researchers.

  (4) designated evaluation methods such as imaging can not be accepted or provided.

Conditions2

Browse More Trials